Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

OBJECTIVE: To assess the safety and effectiveness of imatinib mesylate in the treatment of diffuse cutaneous systemic sclerosis (dcSSc). METHODS: In this phase IIa, open-label, single-arm clinical trial, 30 patients with dcSSc were treated with imatinib 400 mg daily. Patients were monitored monthly...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiera, Robert F, Gordon, Jessica K, Mersten, Jamie N, Magro, Cynthia M, Mehta, Mansi, Wildman, Horatio F, Kloiber, Stacey, Kirou, Kyriakos A, Lyman, Stephen, Crow, Mary K
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086082/
https://www.ncbi.nlm.nih.gov/pubmed/21398330
http://dx.doi.org/10.1136/ard.2010.143974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086082/
https://www.ncbi.nlm.nih.gov/pubmed/21398330
http://dx.doi.org/10.1136/ard.2010.143974

Ejemplares similares